Novel implant for macular telangiectasia gains fast-track designation

The FDA has fast-tracked Neurotech’s implant for stalling central vision loss in people with type 2 macular telangiectasia.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553